TP53 and malignant colon neoplasm: The impaired sensitivity of mutant p53-harboring colon cancer cells to oxaliplatin is also hypothesized to be influenced by cancer stemness (represented by CD133 and CD44 positivity) and Wnt/β-catenin signaling [65].